Skip to content
Triangle logo TriangleGet started
← Study library

NCT04272775 · REGISTRY CONDITION SEARCH

A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1
Status at capture
TERMINATED
Registry last update
2020-03-17

The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK) of ixazomib alone or in combination with lenalidomide and dexamethasone (Rd), and antitumor activity of ixazomib in participants with RRMM.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)

→

outcome · POSTED

Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)

→

outcome · POSTED

Number of Participants With Grade 3 or Higher TEAE Related to Body Weight

→

outcome · POSTED

Number of Participants With Grade 3 or Higher TEAE Related to Vital Signs

→

outcome · POSTED

Number of Participants With Grade 3 or Higher TEAE Related to 12-lead Electrocardiograms (ECGs)

→

outcome · POSTED

Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities

→

outcome · POSTED

Cmax: Maximum Observed Plasma Concentration for Ixazomib

→

outcome · POSTED

Number of Participants Who Achieved Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: 1. Japanese participants with multiple myeloma according to diagnostic criteria. 2. Previously treated with 2 or more regimens including all the following drugs; bortezomib, thalidomide or lenalidomide, corticosteroids. 3. Who have relapsed following the previous therapy or failed to continue the treatment due to their intolerability to the last treatment regimen for myeloma. 4. Measurable disease defined by at least one of the following 3 measurements; Serum M-protein: greater than or equal to (\>=) 1 gram per deciliter (g/dL) (\>= 10 gram per liter \[g/L\]), Urine M-protein: \>= 200 mg/24 hours, Serum free light chain (FLC) assay: involved FLC level \>= 10 milligram per deciliter (mg/dL) (\>= 100 milligram per liter \[mg/L\]), provided that the serum FLC ratio is abnormal. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 6. 20 years or older at giving their informed consent. 7. Must be able to stay in the hospital for Cycle 1 treatment. 8. Must meet the following laboratory criteria at screening; Absolute neutrophil count (ANC): \>=1,000 per cubic millimeter (/mm\^3), Platelet count: \>=75,000/mm\^3, Total bilirubin: \<=1.5\* the upper limit of normal range (ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): less than or equal to (\<=) 3\* ULN, Creatinine clearance: calculated by using Cockcroft-Gault formula; MLN9708 monotherapy cohort: \>=30 milliliter per minute (mL/min); MLN9708 with Rd cohort: \>=60 mL/min. 9. Recovered (\<= Grade 1) from the toxicities of the prior treatments. ANC \>=1,000/mm\^3. 10. Life expectancy of at least 3 months, in the judgment of the investigator. 11. Conforming to proper management guidelines of lenalidomide (MLN9708 with Rd cohort only). Exclusion Criteria: 1. With plasmacytoma only. 2. With plasma cell leukemia. 3. With central nervous system invasion. 4. Radiotherapy within 14 days before enrollment. 5. Other anti-tumor drug administration within 21 days before enrollment. 6. Other investigational products administration within 21 days before enrollment (60 days from the last dose for carfilzomib). 7. Antibody treatment within 42 days before enrollment. 8. Systemic treatment with potent cytochrome P450 (CYP) isozyme 1A2 inhibitors (fluvoxamine, enoxacin), potent CYP3A inhibitors (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole), or potent CYP3A inducers (rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of foods containing Ginkgo biloba extract, St. John's Wort, or grapefruit within 14 days before enrollment. 9. Treatment with corticosteroids greater than (\>) 10 mg of prednisolone per day. Inhaled and topical steroids are permitted. 10. Peripheral neuropathy \>=Grade 2. 11. Diarrhea \>= Grade 2. 12. Major surgery requiring general anesthesia within 14 days before enrollment. 13. Infection requiring systemic antibiotic treatment or other serious infections within 14 days before enrollment. 14. Evidence of concurrent uncontrolled cardiovascular conditions including hypertension, cardiac arrhythmias, New York Heart Association (NYHA) Class III or worse congestive heart failure, angina, myocardial infarction, or cerebral infarction within 6 months before enrollment. 15. Corrected QT interval (QTc) \> 470 milliseconds on a 12-lead ECG obtained during the screening period. 16. Tested positive for human immunodeficiency virus (HIV) antibody, hepatitis B virus surface antigen (HBs antigen), or hepatitis C virus (HCV) antibody during the screening period. 17. Hypersensitivity to MLN9708 (including excipients), boron, or boron-containing drugs. 18. Hypersensitivity to lenalidomide, or dexamethasone, or excipients contained in the formulation of each drug (MLN9708 with Rd cohort only). 19. Known gastrointestinal diseases (difficulty swallowing, inflamed gastroenteritis, and Crohn disease), or gastrointestinal procedure (endoscopic procedure is permitted), that could interfere with the oral absorption or tolerance of the study treatment. 20. Uncontrolled diabetes mellitus. 21. A history of interstitial lung disease or lung fibrosis, or a current complication of interstitial lung disease or lung fibrosis diagnosed by diagnostic chest imaging. 22. Prior or current complications of deep vein thrombosis or pulmonary embolism (MLN9708 with Rd cohort only). 23 Diagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have complete resection. 24\. Who do not consent to use adequate contraceptive precautions (example, condoms and oral contraceptives) during the following term: * For women with childbearing potential, from when giving their consent through 3 months after the last dose of MLN9708, dexamethasone, or lenalidomide * For men having their partners with childbearing potential, from giving their consent through 4 months after last dose of MLN9708, dexamethasone, or lenalidomide. 25\. Pregnant (example, positive for pregnancy test) or lactating. Lactation is prohibited from the first dose through 6 months after the last dose of MLN9708, dexamethasone, and lenalidomide. 26\. Use of an investigational medical device within 28 days before enrollment. 27. Any inabilities that could potentially interfere with the consent or completion of treatment according to this protocol. 28\. Having difficulties in participation to this study by the investigator's judgment.
healthy Volunteers
false
minimum Age
20 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Ixazomib 4.0 milligram (mg), capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
    intervention Names
    1. Drug: Ixazomib
    label
    Cohort 1: Ixazomib 4.0 mg
    type
    EXPERIMENTAL
  2. description
    Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 milligram per day (mg/day), capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 62.
    intervention Names
    1. Drug: Ixazomib
    2. Drug: Lenalidomide
    3. Drug: Dexamethasone
    label
    Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone
    type
    EXPERIMENTAL
  3. description
    Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
    intervention Names
    1. Drug: Ixazomib
    label
    Cohort 3: Ixazomib 5.5 mg
    type
    EXPERIMENTAL
  4. description
    Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 mg/day, capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 87.
    intervention Names
    1. Drug: Ixazomib
    2. Drug: Lenalidomide
    3. Drug: Dexamethasone
    label
    Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Cohort 1: Ixazomib 4.0 mg
    2. Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone
    3. Cohort 3: Ixazomib 5.5 mg
    4. Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone
    description
    Ixazomib capsules.
    name
    Ixazomib
    other Names
    1. MLN9708
    type
    DRUG
  2. arm Group Labels
    1. Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone
    2. Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone
    description
    Lenalidomide capsules.
    name
    Lenalidomide
    type
    DRUG
  3. arm Group Labels
    1. Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone
    2. Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone
    description
    Dexamethasone tablets.
    name
    Dexamethasone
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
SEQUENTIAL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
14
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    DLT:Any following adverse events (AEs) possibly related to ixazomib assessed by Common Terminology Criteria for AEs (CTCAE) version 4.03; Grade 4 neutropenia/thrombocytopenia lasting \>7 consecutive days; Grade 3/greater neutropenia with fever/infections; Grade 3/greater thrombocytopenia with clinically significant bleeding; platelet count less than (\<)10,000 per cubic meter(/mm\^3); Grade 2 peripheral neuropathy with pain/Grade 3 or greater peripheral neuropathy; Grade 3/greater nonhematologic toxicities with exceptions of arthralgia/myalgia, fatigue lasting \<7 days manageable nausea/emesis with antiemetic prophylaxis, diarrhea that is controlled with supportive care; treatment delay of \>14 days at start of Cycle 2 due to failure of hematologic/nonhematologic recovery; Other Grade 2/greater ixazomib related nonhematologic toxicities required permanent discontinuation of ixazomib;Inability to receive at least 80% of planned lenalidomide doses due to the AEs related to ixazomib.
    measure
    Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)
    time Frame
    From Cycle 1 Day 1 until Cycle 2 Day 1 (Cycle length is equal to [=] 28 days)
  2. measure
    Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
    time Frame
    Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
  3. description
    Body weight abnormalities were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE).
    measure
    Number of Participants With Grade 3 or Higher TEAE Related to Body Weight
    time Frame
    Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
  4. description
    Vital signs were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE).
    measure
    Number of Participants With Grade 3 or Higher TEAE Related to Vital Signs
    time Frame
    Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
  5. description
    12-lead ECGs were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE).
    measure
    Number of Participants With Grade 3 or Higher TEAE Related to 12-lead Electrocardiograms (ECGs)
    time Frame
    Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
  6. description
    Laboratory tests abnormalities were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE).
    measure
    Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities
    time Frame
    Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
  7. measure
    Cmax: Maximum Observed Plasma Concentration for Ixazomib
    time Frame
    Days 1 and 15 of Cycle 1: pre-dose and at multiple time points (15, 30, 60, and 90 minutes and 2, 4, 8, 24, 48, 96, and 168 hours) post-dose (Cycle length=28 days)
secondary Outcomes
  1. description
    Number of participants who achieved CR, PR, VGPR were assessed in accordance to International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma. CR: No immunofixation on serum and urine, disappearance of soft tissue plasmacytomas and \<5% plasma cells in bone marrow. Normal serum free light chain (SFLC) ratio if disease measurable only by SFLC. VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or greater than or equal to (\>=) 90% decrease in serum M-protein with urine M-protein \<100 milligram per 24 hours (mg/24 hrs). If disease measurable only by SFLC, \>= 90% decrease in the difference between involved and uninvolved FLC levels (dFLC). PR: \>= 50% reduction of serum M-protein and \>= 90% reduction in urine M-protein or to \<200 mg/24 hrs, or a \>= 50% decrease in dFLC. A \>=50% decrease in the size of soft tissue plasmacytomas present at baseline
    measure
    Number of Participants Who Achieved Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR)
    time Frame
    Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
Full study description
brief Summary
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK) of ixazomib alone or in combination with lenalidomide and dexamethasone (Rd), and antitumor activity of ixazomib in participants with RRMM.
detailed Description
The drug being tested in this study is called ixazomib. This study will evaluate the tolerability, safety, and PK of ixazomib administered alone or in combination with lenalidomide and dexamethasone in participants with relapsed and/or refractory multiple myeloma. This study will enroll approximately 24 participants (3 to 6 participants in each dose-escalation cohort). Participants will be assigned to receive treatment in one of the four treatment cohorts: * Cohort 1: Ixazomib 4.0 mg * Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone * Cohort 3: Ixazomib 5.5 mg * Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone This multi-center trial will be conducted in Japan. The overall time to participate in this study is approximately 7 years. Participants will make a final visit 29 days after receiving their last dose of drug for a follow-up assessment.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-6e0efd5ae6d1f34d8127
      requested nct id
      NCT04272775
      primary nct id
      NCT04272775
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      37a027fad1655b48875157c68286fc7c79a8a9ae04e6e3e303700f5e491951c0
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-6e0efd5ae6d1f34d8127
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT04272775
      occurrences
      1. context exact
        NCT04272775
        end
        11
        exact text
        NCT04272775
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/656/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      063cdfd15010a2101f26651309d1342b290a1db5868d16fe1825cdafd931f17e

    Preserved source evidence · Not medical advice